CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Financial Statements and Exhibits

CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Financial Statements and ExhibitsItem 9.01

2

CATALYST PHARMACEUTICALS, INC. ExhibitEX-99.1 2 d480303dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Catalyst Pharmaceuticals Completes Enrollment in Second Phase 3 Trial of Firdapse® in Patients with Lambert-Eaton Myasthenic Syndrome — Top-Line Results Expected in Early December — — Required Abuse Liability Studies Completed — CORAL GABLES,…To view the full exhibit click here
About CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company’s Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company’s CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette’s Disorder. The Company’s CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette’s Disorder, and epilepsy.